News

Video

CAR T-Cell Therapy Yescarta Continues to Demonstrate Durable Responses in Follicular Lymphoma

Author(s):

Fact checked by:

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

Treatment with the CAR T-cell therapy Yescarta (axicabtagene ciloleucel) continued to show deep and durable responses, representing a potentially curative treatment option for patients with relapsed/refractory follicular lymphoma, according to Dr. Sattva S. Neelapu.

Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.

Neelapu sat down for an interview with CURE® to discuss the five-year follow-up data from the phase 2 ZUMA-5 trial evaluating the CAR T-cell therapy in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Transcript:

Compared with other therapies that are currently available for relapsed/refractory follicular lymphoma — including therapies such as [Rituxan (rituximab)] and [Revlimid (lenalidomide)], or [Rituxan] with chemotherapy such as [Treanda (bendamustine)] or other chemotherapy regimens, [as well as] targeted therapies such as [Tazverik (tazemetostat)] or BTK inhibitors such [Brukinsa (zanubrutinib)] — we saw that the durability of response is much, much longer with the CAR T-cell therapy Yescarta. In fact, with most of the therapies, the median duration of response is about one to one and a half years in the third-line setting and beyond for follicular lymphoma, whereas here we are seeing a five-year median duration of response, which I think is remarkable.

Most of these therapies are not considered curative for follicular lymphoma, but based on this five-year analysis and the plateau in the lymphoma-specific progression-free survival [PFS], CAR T-cell therapy is potentially curative for relapsed/refractory follicular lymphoma. Even compared with T cell engagers, which are more recently approved for follicular lymphoma, such as mosunetuzumab which has a median duration of response and a PFS in the two-year range, whereas now we are seeing five-year durability of responses with CAR T-cell therapy.

Transcript was edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses